Navigation Links
Tight Blood Pressure Control Doesn't Help All Diabetics: Study
Date:7/6/2010

By Amanda Gardner
HealthDay Reporter

TUESDAY, July 6 (HealthDay News) -- Lower may not be better when it concerns blood pressure levels in type 2 diabetics who also have heart disease.

New research finds that patients with diabetes and coronary artery disease did not have fewer strokes or heart attacks, and actually were more likely to die when their blood pressure was maintained under 130 mm Hg, compared to patients with "usual blood pressure control," putting them in the 130 to 140 range.

In healthy adults, blood pressure levels of 120/80 are recommended.

"We found that after a mean follow-up of just under three years in patients with diabetes and coronary artery disease, lowering systolic blood pressure [the top number] to less than 130 . . . did not have any benefit compared to lowering blood pressure to between 130 and 140," said Rhonda Cooper-DeHoff, lead author of the study published in the July 7 issue of the Journal of the American Medical Association.

These findings, along with similar data recently released from the large ACCORD study, would suggest that "lowering blood pressure intensively does not provide any benefit over and above usual blood pressure reduction," said Cooper-DeHoff, who is associate professor of pharmacotherapy and translational research and division of cardiovascular medicine at the Colleges of Pharmacy and Medicine, University of Florida, Gainesville.

Time would be better spent focusing on other modifiable heart disease risk factors, such as cholesterol, she advised.

Various organizations, including the American Diabetes Association, currently recommend that diabetics keep their blood pressure under 130/80 mm Hg, but it's been less clear what to recommend for patients with type 2 diabetes and coronary artery disease.

To this end, the researchers involved in the new study analyzed data on 6,400 type 2 diabetics aged 50 or over who also had coronary artery disease. The participants were part of a larger trial investigating whether specific medication regimens were better than others for preventing heart attacks and other long-term heart problems.

Volunteers first received either a calcium antagonist or beta blocker, then an ACE inhibitor or a diuretic or both. The goal was to reach blood pressure levels of 130/85.

Individuals in the study who had blood pressure between 130 mm Hg and 140 mm Hg (usual control) and those who maintained tight control (less than 130 mm Hg) had roughly the same rate of cardiovascular events.

And, for the first time, the results showed that individuals with systolic blood pressure under 120 had a 15 percent higher risk of dying than those with the higher blood pressure readings.

"We don't need to push below 130 so maybe we save a blood pressure medication and save some of those adverse effects associated with extra [blood pressure] medication and concentrate on some other goals that are still important in patients with diabetes," said Cooper-DeHoff.

The trial was partially funded by Abbott Laboratories.

More information

The American Diabetes Association has more on living with type 2 diabetes and high blood pressure.

SOURCES: Rhonda Cooper-DeHoff, Pharm.D., associate professor, department of pharmacotherapy and translational research and division of cardiovascular medicine, Colleges of Pharmacy and Medicine, University of Florida, Gainesville; July 7, 2010, Journal of the American Medical Association


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Tight Blood Sugar Control in Older Diabetics May Not Reduce Heart Risk
2. Tight Blood Sugar Control May Not Harm Diabetics
3. FDA Tightens Oversight of Home Medical Devices
4. IBM Enterprise CloneDR Helps Enterprises Transform Bloated COBOL into Clean, Tight, and Maintainable Code
5. FDA Tightens Controls on Anemia Drugs
6. Tight Blood Sugar Control May Raise Risk of Death
7. Tighter Blood Sugar Control Not Best for Some Diabetics
8. Researchers identify factors behind blood-making stem cells
9. Diagnostic blood test can identify rare lung disease
10. Insulin Pump With Blood Sugar Sensor May Improve on Injections
11. Sensor and insulin pump results in better blood-sugar control in all age groups with diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... GROVE, ILL. (PRWEB) , ... January 24, 2017 ... ... odor abatement solutions, announced that it has officially formed a distribution partnership with ... equipment for the industrial odor management industry. , Through the agreement, OMI Industries ...
(Date:1/24/2017)... ... ... This Saturday, January 28, the BCFA presents more than 20 local performances including ... musicians Yifan Zhou, Mara McClain & Sarah Nordlund Dennis. Local chefs and restaurants provide ... at Chinese games, crafts & more. Festivities begin at 11:00 am and end at ...
(Date:1/24/2017)... ... , ... The results from the American Cancer Society’s newest report ... cancer patients: incidents of cancer is down as is the likelihood of prostate cancer ... has dropped from its peak of 215.1 in 1991 to 161.2 in 2014 (per ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... unveiled its latest award-winning bottles, designed specifically to optimize the drinking experience for ... Agua is renowned for introducing the world’s first untouched bottled water purposed exclusively ...
(Date:1/24/2017)... ... January 24, 2017 , ... “Choosing Wisdom-Solomon’s ... finances, friendship, marriage, leadership, gossip, prostitution, adultery, anger, and common sense. , ... Judith Coats and Dr. David Coats. In September of 1983, they flew to ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... Jan. 24, 2017   Keneric Healthcare , ... cost effective patient care products, today announced their ... expand the reach of both companies by leveraging ... expertise. Angelini Pharma Inc ... now include Keneric Healthcare,s RTD™ Wound Dressing (antibacterial/antifungal). ...
(Date:1/24/2017)... , January 24, 2017 Stock-Callers.com ... Zoetis Inc. (NYSE: ZTS ), Mallinckrodt PLC (NYSE: ... ), and Diplomat Pharmacy Inc. (NYSE: DPLO ). ... for significant change in 2017 for the Generic Drugs industry, ... because of the industry,s current growth, and a speedier FDA ...
(Date:1/24/2017)... -- Laboratory Markets Limited has completed a comprehensive market ... both clinical and research laboratory settings. This study, which ... $6.8 billion and growing to $9.2 billion (CAGR of ... of mass spectrometry across more than 5,200 clinical and ... in the use of mass spectrometry in terms of ...
Breaking Medicine Technology: